Gencurix Inc. (KOSDAQ:229000)

Market Cap	40.53B +43.1%
Revenue (ttm)	3.39B +25.7%
Net Income	-12.55B
EPS	-877.76
Shares Out	23.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	130,241
Average Volume	824,459
Open	1,786.00
Previous Close	1,804.00
Day's Range	1,730.00 - 1,814.00
52-Week Range	1,385.00 - 2,410.00
Beta	0.72
RSI	47.73
Earnings Date	Mar 20, 2026

About Gencurix

Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detection. The company has a strategic alliance with Qiagen N.V. for the development of oncology assays for use on the QIAcuityDx platform. The company was fo...

• Industry: Medical - Specialties
• Sector: Healthcare
• Founded: 2011
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 229000

Financial Performance

In 2023, Gencurix's revenue was 2.60 billion, an increase of 1.60% compared to the previous year's 2.56 billion. Losses were -19.26 billion, -21.70% less than in 2022.